MVM Partners
MVM Partners is a healthcare investment firm supporting high-growth businesses across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and life sciences tools.
- Healthcare and life sciences private equity investment firm
- Healthcare & Life Sciences PEF
- Tier III
Overview
MVM Partners is a healthcare investment firm supporting high-growth businesses across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and life sciences tools.
The firm operates across the United States and Europe and focuses on companies with differentiated products, technologies, or scientific capabilities addressing meaningful unmet needs. Its investments commonly require judgment regarding intellectual property, regulatory pathways, clinical evidence, commercialization, and strategic exit markets. Within The Economy Wiki, the firm is connected to the Healthcare & Life Sciences PEF market category.
Firm facts
| Institution | MVM Partners |
| Type | Healthcare and life sciences private equity investment firm |
| Headquarters | Boston, United States, and London, United Kingdom |
| Founded | 1997 |
| Primary ranking focus | Healthcare & Life Sciences PEF |
| Highest 2026 tier | Tier III |
Activities and investment capabilities
MVM’s transatlantic model helps portfolio companies access management networks, customers, capital, and potential strategic partners in two major healthcare innovation regions. Its concentrated approach allows close engagement with management teams.
Healthcare investing
Equity investment across healthcare services, products and technology.
Life sciences exposure
Capital for pharmaceutical, biotechnology, medtech and outsourced-service platforms.
Sector value creation
Support informed by regulation, reimbursement, clinical workflows and market access.
Strategy and transaction coverage
Strategy and sector coverage
Healthcare services; life sciences; pharmaceuticals; medtech; diagnostics; healthcare IT
Transaction and ownership contexts
Buyouts; growth investments; recapitalizations; platform formation; add-on acquisitions
Market position
MVM Partners fits Tier III because it brings long-standing life sciences and medtech growth expertise to the ranking. Its mandate is narrower and more innovation-oriented than conventional buyout private equity, but institutionally significant within healthcare growth capital.
MVM Partners is assessed within the Healthcare & Life Sciences PEF framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
MVM Partners is recognized Tier III in Top 30 Healthcare & Life Sciences PEF 2026. The ranking compares firms by institutional relevance, specialist capability, investment activity, operating depth and market positioning. Comparable-firm links below support navigation and do not imply that every institution competes for every transaction or asset.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through MVM Partners’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to MVM Partners as the public-facing investment organization. Individual funds, management companies, advisers and regulated entities may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | MVM Partners |
| Headquarters | Boston, United States, and London, United Kingdom |
| Public website | mvm.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the investment, diligence, financing and value-creation themes relevant to this firm:
- The Mid-Market Advantage in Healthcare Private Equity
- Middle-Market Private Equity: Returns, Scale and Manager Selection
- Private Equity Technology Due Diligence in the AI Era
